Skip to main content

Cordova Ashley's Form 4 filing

NovoCure Ltd (NVCR) · filed Mar 3, 2025

Accession no.
0001562180-25-001833
Filed
Mar 3, 2025
Trade date
Feb 27-28, 2025
Filing delay
4 days
Rule 10b5-1 plan
Not checked

This filing lists 3 non-derivative transactions. Open-market sales total $266.1K. It was filed 4 days after the trade.

This filing was later replaced by the amendment 0001562180-25-001916 (Mar 3, 2025). Trade tables on this site use the amended version.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Cordova AshleyCIK 0001822014Officer (Chief Executive Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Feb 27, 2025Ordinary SharesSSaleDisposed−9,345$19.92F1−$186,152.4210,207Direct
Feb 27, 2025Ordinary SharesSSaleDisposed−1,808$20.55F2−$37,154.4208,399Direct
Feb 28, 2025Ordinary SharesSSaleDisposed−2,341$18.28F3−$42,793.48206,058Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

On February 27, 2025, the reporting person sold 9,345 shares in multiple trades at prices ranging from $19.41 to $20.4033. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.

Referenced by the price of 1 transaction in Table I.

F2

On February 27, 2025, the reporting person sold 1,808 shares in multiple trades at prices ranging from $20.41 to $20.85. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.

Referenced by the price of 1 transaction in Table I.

F3

On February 28, 2025, the reporting person sold 2,341 shares in multiple trades at prices ranging from $18.175 to $18.765. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)